Horizon Pharma Inc (HZNP) 8.85 $HZNP
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets
Marketwire - Tue Aug 05, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. (NASDAQ: POZN) has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application numbers 14/231,971, and 14/244,471, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover Horizon and POZEN'S U.S. approved product VIMOVO(R) (naproxen / esomeprazole magnesium) delayed release tablets.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Corning and Windstream are big market movers
AP - Tue Jul 29, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Horizon Pharma to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 7, 2014
Marketwire - Tue Jul 29, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its second quarter 2014 financial results will be released on Thursday, August 7, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.
Why Horizon Pharmaceuticals (HZNP) Is Plummeting Today
at The Street - Mon Jul 28, 1:25PM CDT
Horizon Pharmaceuticals (HZNP) plummeted Monday after the company said CVS (CVS) and Express Scripts (ESRX) would put Horizon's two best-selling drugs on their exclusion lists at the beginning of 2015.
Video: Horizon Pharma Drugs Dumped By Pharmacies
at Investor's Business Daily - Mon Jul 28, 10:14AM CDT
Shares of specialty drugmaker Horizon Pharma (HZNP) were down 30% on the stock market today after two major pharmacy benefit managers removed its drugs from their formularies. Horizon disclosed in an SEC filing that Express Scripts (ESRX) and...
Access to Horizon Pharma Drugs Cut By Two Leading PBMs
at The Street - Mon Jul 28, 9:56AM CDT
Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jul 08, 1:11AM CDT
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
The 5 Best Healthcare Stocks so Far in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 8:30AM CDT
Healthcare stocks put up impressive returns last year and are trumping the S&P 500 yet again this year. The S&P health care select index ETF (XLV) is up more than 10% this year and the iShares Nasdaq biotechnology ETF (IBB) has gained...
Salix Pharmaceuticals Surges on Positive IBS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 5:15PM CDT
Salix Pharmaceuticals, Ltd.'s (SLXP) announced encouraging data from a phase III study on Xifaxan 550 mg.
Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.
Early Briefing on Pharma Stocks -- Research on Novartis, Akorn, Horizon Pharma, and Mallinckrodt
PR Newswire - Wed Jul 02, 5:50AM CDT
On Tuesday, July 1, 2014, the NASDAQ Composite ended at 4,458.65, up 1.14%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,956.07, and the S&P 500 closed at 1,973.32, up 0.67%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.38, up 1.26%, with the index advancing 4.64% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novartis AG (NYSE: NVS), Akorn Inc. (NASDAQ: AKRX), Horizon Pharma Inc. (NASDAQ: HZNP) and Mallinckrodt PLC (NYSE: MNK). Free technical research on NVS, AKRX, HZNP and MNK can be downloaded upon signing up at:
Market Expansion, Merger Agreements, Management Transitions, and Market Activity - Analyst Notes on Intuitive Surgical, Auxilium, Horizon Pharma, Tesaro and ArQule
PR Newswire - Wed Jul 02, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Horizon Pharma, Inc. (NASDAQ: HZNP), Tesaro, Inc. (NASDAQ: TSRO) and ArQule Inc. (NASDAQ: ARQL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4352-100free.
Walgreen 3Q profit jumps but misses expectations
By TOM MURPHY - AP - Tue Jun 24, 11:10AM CDT
Walgreen's fiscal third quarter earnings jumped 16 percent compared with last year, aided in part by a lower income tax rate, but the drugstore chain's performance again fell short of Wall Street's expectations.
Horizon Pharma enters into USD300m senior secured credit agreement for planned acquisition of Vidara
M2 - Fri Jun 20, 6:07AM CDT
Pharmaceutical company Horizon Pharma (NASDAQ:HZNP) said on Thursday that it expects to receive USD300m under a five year senior secured credit facility with lenders.
Horizon Pharma Announces Execution of $300 Million Senior Secured Credit Agreement in Connection With the Proposed Acquisition of Vidara
Marketwire - Thu Jun 19, 6:01AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement with a group of lenders to provide Horizon with $300 million in financing through a five year senior secured credit facility. Funding is expected to occur coincident with the closing of the proposed acquisition of Vidara Therapeutics International Ltd. This agreement replaces the $250 million bridge loan commitment received from Deerfield Management Company, L.P., which the Company announced on March 19, 2014.
Horizon Pharma Announces Robert J. De Vaere to Retire and Names Paul W. Hoelscher Chief Financial Officer
Marketwire - Wed Jun 18, 6:00AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Robert J. De Vaere, its current Chief Financial Officer, will retire on September 30, 2014. The Company has also named Paul W. Hoelscher as Executive Vice President, Finance, effective June 23, 2014 and its Chief Financial Officer, effective October 1, 2014. At the time of his retirement, Mr. De Vaere will enter into a one-year consulting agreement with the Company to support the ongoing integration of Vidara following the closing of the acquisition and to provide general business support and guidance as the company seeks to continue its recent growth, both organically and through acquisition.
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets
Marketwire - Tue Aug 05, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. (NASDAQ: POZN) has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application numbers 14/231,971, and 14/244,471, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover Horizon and POZEN'S U.S. approved product VIMOVO(R) (naproxen / esomeprazole magnesium) delayed release tablets.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Corning and Windstream are big market movers
AP - Tue Jul 29, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Horizon Pharma to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 7, 2014
Marketwire - Tue Jul 29, 6:30AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its second quarter 2014 financial results will be released on Thursday, August 7, 2014. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.
Why Horizon Pharmaceuticals (HZNP) Is Plummeting Today
at The Street - Mon Jul 28, 1:25PM CDT
Horizon Pharmaceuticals (HZNP) plummeted Monday after the company said CVS (CVS) and Express Scripts (ESRX) would put Horizon's two best-selling drugs on their exclusion lists at the beginning of 2015.
Video: Horizon Pharma Drugs Dumped By Pharmacies
at Investor's Business Daily - Mon Jul 28, 10:14AM CDT
Shares of specialty drugmaker Horizon Pharma (HZNP) were down 30% on the stock market today after two major pharmacy benefit managers removed its drugs from their formularies. Horizon disclosed in an SEC filing that Express Scripts (ESRX) and...
Access to Horizon Pharma Drugs Cut By Two Leading PBMs
at The Street - Mon Jul 28, 9:56AM CDT
Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jul 08, 1:11AM CDT
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
The 5 Best Healthcare Stocks so Far in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 8:30AM CDT
Healthcare stocks put up impressive returns last year and are trumping the S&P 500 yet again this year. The S&P health care select index ETF (XLV) is up more than 10% this year and the iShares Nasdaq biotechnology ETF (IBB) has gained...
Salix Pharmaceuticals Surges on Positive IBS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 5:15PM CDT
Salix Pharmaceuticals, Ltd.'s (SLXP) announced encouraging data from a phase III study on Xifaxan 550 mg.
Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.
Early Briefing on Pharma Stocks -- Research on Novartis, Akorn, Horizon Pharma, and Mallinckrodt
PR Newswire - Wed Jul 02, 5:50AM CDT
On Tuesday, July 1, 2014, the NASDAQ Composite ended at 4,458.65, up 1.14%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,956.07, and the S&P 500 closed at 1,973.32, up 0.67%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.38, up 1.26%, with the index advancing 4.64% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novartis AG (NYSE: NVS), Akorn Inc. (NASDAQ: AKRX), Horizon Pharma Inc. (NASDAQ: HZNP) and Mallinckrodt PLC (NYSE: MNK). Free technical research on NVS, AKRX, HZNP and MNK can be downloaded upon signing up at:
Market Expansion, Merger Agreements, Management Transitions, and Market Activity - Analyst Notes on Intuitive Surgical, Auxilium, Horizon Pharma, Tesaro and ArQule
PR Newswire - Wed Jul 02, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Horizon Pharma, Inc. (NASDAQ: HZNP), Tesaro, Inc. (NASDAQ: TSRO) and ArQule Inc. (NASDAQ: ARQL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4352-100free.
Walgreen 3Q profit jumps but misses expectations
By TOM MURPHY - AP - Tue Jun 24, 11:10AM CDT
Walgreen's fiscal third quarter earnings jumped 16 percent compared with last year, aided in part by a lower income tax rate, but the drugstore chain's performance again fell short of Wall Street's expectations.
Horizon Pharma enters into USD300m senior secured credit agreement for planned acquisition of Vidara
M2 - Fri Jun 20, 6:07AM CDT
Pharmaceutical company Horizon Pharma (NASDAQ:HZNP) said on Thursday that it expects to receive USD300m under a five year senior secured credit facility with lenders.
Horizon Pharma Announces Execution of $300 Million Senior Secured Credit Agreement in Connection With the Proposed Acquisition of Vidara
Marketwire - Thu Jun 19, 6:01AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement with a group of lenders to provide Horizon with $300 million in financing through a five year senior secured credit facility. Funding is expected to occur coincident with the closing of the proposed acquisition of Vidara Therapeutics International Ltd. This agreement replaces the $250 million bridge loan commitment received from Deerfield Management Company, L.P., which the Company announced on March 19, 2014.
Horizon Pharma Announces Robert J. De Vaere to Retire and Names Paul W. Hoelscher Chief Financial Officer
Marketwire - Wed Jun 18, 6:00AM CDT
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Robert J. De Vaere, its current Chief Financial Officer, will retire on September 30, 2014. The Company has also named Paul W. Hoelscher as Executive Vice President, Finance, effective June 23, 2014 and its Chief Financial Officer, effective October 1, 2014. At the time of his retirement, Mr. De Vaere will enter into a one-year consulting agreement with the Company to support the ongoing integration of Vidara following the closing of the acquisition and to provide general business support and guidance as the company seeks to continue its recent growth, both organically and through acquisition.
